| |
|
MRI Spectroscopy
The next Greatest Prostate Cancer Diagnostic Test
Dr. Wheeler expects to bring the next greatest prostate cancer detection
technology to Sarasota, Florida.
Specifically, Magnetic Resonance Imaging Spectroscopy (MRIS), applied with an ultrasound type hand-held probe, will
provide a unique "finger print" representation of cancer (if present) as it evaluates the by-products of metabolism at the
prostate cellular level. Peter Scardino, M.D., Medical Director of the department of Urology at Memorial Sloan-Kettering
has been quoted as saying, "This is the next greatest advancement in prostate cancer diagnostic testing".
According to Hedvig Hricak, M.D., Chair of the Department of Radiology at Memorial Sloan-Kettering:
…"Prostate cancer
treatment should be tailored to the individual patient, while the MRIS is a non-invasive diagnostic technology that gives
the patient and physician a clear road map for this treatment."
Candidates for MRI-S |
| • |
Men who want to find prostate cancer that can't detected with a
Digital Exam or ultrasound with Biopsy |
| • |
Men who want to avoid a biopsy including men with a PSA
value between 1.0-4.0 ng/ml (70-80% of prostate biopsies are negative) |
| • |
Men who want to avoid a biopsy who understands that a biopsy procedure
can spread cancer beyond the prostate |
| • |
Men who have PSA value in excess of 1.0 ng/ml, with a family history
of prostate cancer |
| • |
Men who have had a persistently high PSA value with or without a
negative biopsy |
| • |
Men with an elevated PSA (greater than 4.0 ng/ml) who have never had a
biopsy but choose to improve the odds of finding a cancer if present; (Only 20-30% of all prostate biopsies
traditionally performed yield a cancer) |
| • |
Men who choose to monitor a low level of prostate cancer and live with
the disease; similar to man living with arthritis or diabetes, without the risk of impotency or incontinence |
| • |
Men who have experienced a biopsy one or more times and want to
improve the sensitivity of diagnosis of cancer, if present |
| • |
Physicians who want to localize prostate cancer so that fewer biopsies
are required, when either a nodule and/or PSA suggests suspicion |
| • |
Patients who elect to choose a comprehensive, conservative alternative
to repeat biopsies when they receive the diagnosis of High Grade Prostatic Intra-epithelial Neoplasia (HGPIN) |
| • |
Patients (and physicians) who want to evaluate the true extent of the
disease when a prostate biopsy is positive |
|
